Dendritic Cells Profile in Inflamed Colonic Mucosa Predicts Response to Tumor Necrosis Factor Alpha Inhibitors

We aimed to investigate the effects of tumor necrosis factor-alpha (TNF-a) inhibitors on intestinal dendritic cells of patients with inflammatory bowel disease and their potential role in predicting response to treatment. Intestinal biopsies were obtained from 30 patients with inflammatory bowel disease (16 Crohn's disease and 14 ulcerative colitis patients) before and after the treatment with TNF a inhibitors (infliximab 13 patients, adalimumab 17 patients).
Conclusion:
DCs were isolated from intestinal mucosal biopsies. Unlabelled cells and isotype control were used to facilitate separation between negative and positive cells. Plasmacytoid DCs are CD123+/CD303+ and conventional (myeloid) DCs are CD11c+ and were further investigated for CD80, CD83, CD86 expression. Frequency of CD103+/CD103-DCs was presenting among the cDCs.
Notes:
We prospectively investigated in vivo effects of TNF-a inhibitors on mucosal DCs in 30 IBD patients. This study confirmed previous observations on cDCs changes after treatment with TNF-a inhibitors. Patients responding to treatment with TNF-a inhibitors had significantly higher proportion of conventional dendritic cells with higher expression of HLA-DR in inflamed mucosa before treatment compared to non-responders. To standardize voltage settings across samples acquired on different days BD FACS Diva CS&T beads were run every day. The compensation was made with BD CompBeads.